The U.S. FDA Approves Remibrutinib (Rhapsido, Novartis) for CSU
The US Food and Drug Administration (FDA) has approved remibrutinib (Rhapsido, Novartis) as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment.